Maxim Group analyst Jason McCarthy maintained a Buy rating on Field Trip Health (FTRP – Research Report) yesterday and set a price target of $11.00. The company’s shares closed last Monday at $4.32, close to its 52-week low of $4.10.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.4% and a 26.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.
Currently, the analyst consensus on Field Trip Health is a Strong Buy with an average price target of $12.36, implying a 186.1% upside from current levels. In a report issued on November 10, Bloom Burton also maintained a Buy rating on the stock with a $14.00 price target.
Field Trip Health’s market cap is currently $249.7M and has a P/E ratio of -7.60. The company has a Price to Book ratio of 3.12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Field Trip is a global leader in the development and delivery of psychedelic therapies. With Field Trip Discovery, the company’s research division, leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, and its Field Trip Health division building centers for psychedelic therapies across North America and Europe along with the digital and technological tools that will enable massive scale.
Read More on FTRP: